KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Short-term Investments (2016 - 2025)

Novavax (NVAX) has 14 years of Short-term Investments data on record, last reported at $494.4 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 25.85% year-over-year to $494.4 million; the TTM value through Dec 2025 reached $494.4 million, up 25.85%, while the annual FY2025 figure was $494.4 million, 25.85% up from the prior year.
  • Short-term Investments reached $494.4 million in Q4 2025 per NVAX's latest filing, roughly flat from $494.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $494.9 million in Q3 2025 and bottomed at $2.2 million in Q1 2021.
  • Average Short-term Investments over 3 years is $364.6 million, with a median of $381.1 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: plummeted 96.09% in 2021, then skyrocketed 47.33% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $2.2 million in 2021, then skyrocketed by 17361.69% to $392.9 million in 2024, then grew by 25.85% to $494.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $494.4 million in Q4 2025, $494.9 million in Q3 2025, and $358.6 million in Q2 2025.